NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH)
Status:
Terminated
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The design of the study is a standard double-blind design, which is needed in this study to
allow for unbiased evaluation of efficacy and safety. The effect of the additional impact of
testosterone replacement therapy in hypogonadal men on muscle strength and quality of life in
comparison to physical exercise alone will be assessed. Treatment duration will be 54 weeks,
to monitor the increase as well as the "steady state" of the parameters assessed.